News

Rheumatology Advisor1d

Ianalumab Reduces Sjögren Disease Activity in Late Stage Trials

Ianalumab is a fully human monoclonal antibody designed to deplete B cells via antibody-dependent cellular toxicity and inhibit BAFF-R-mediated signals of B cell function and survival.
University at Buffalo3d

UB dental professor studying immune system’s role in Sjögren’s disease

Jill M. Kramer, DDS, PhD, associate professor in the Department of Oral Biology at the University at Buffalo School of Dental ...

Telitacicept Achieved Primary Endpoint in Phase 3 Clinical Study for Primary Sjögren's Disease with Telitacicept, a Dual BAFF/APRIL Inhibitor

Phase 3 results position telitacicept as potential best-in-disease profile in primary Sjögren's disease Telitacicept ...
Fierce Biotech6d

Novartis scores double phase 3 win in Sjögren's syndrome, succeeding where rivals failed

Novartis may have abandoned one Sjögren's syndrome asset this year, but it looks like the drugmaker has a winner on its hands ...
Clinical Trials Arena on MSN3d

RemeGen’s telitacicept achieves Phase III win in Sjögren’s syndrome

The drug met its primary endpoints in a Chinese trial, while a Phase III trial in Sjögren's syndrome is currently underway in ...